Zobrazeno 1 - 10
of 50
pro vyhledávání: '"M S, Simberkoff"'
Publikováno v:
New England Journal of Medicine. 327:814-816
Publikováno v:
Inquiry : a journal of medical care organization, provision and financing. 37(1)
This study estimates the impact of clinical and socioeconomic characteristics on health care use for HIV-infected patients. Data come from the Department of Veterans Affairs (VA) HIV Registry, which electronically extracts data from patients' automat
Autor:
W A, O'Brien, P M, Hartigan, D, Martin, J, Esinhart, A, Hill, S, Benoit, M, Rubin, M S, Simberkoff, J D, Hamilton
Publikováno v:
The New England journal of medicine. 334(7)
Clinical trials of antiretroviral drugs can take years to complete because the outcomes measured are progression to the acquired immunodeficiency syndrome (AIDS) or death. Trials could be accelerated by the use of end points such as changes in CD4+ l
Autor:
P K, Sharkey, J R, Graybill, E S, Johnson, S G, Hausrath, R B, Pollard, A, Kolokathis, D, Mildvan, P, Fan-Havard, R H, Eng, T F, Patterson, J C, Pottage, M S, Simberkoff, J, Wolf, R D, Meyer, R, Gupta, L W, Lee, D S, Gordon
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 22(2)
The study objective was to obtain preliminary information regarding the safety and efficacy of amphotericin B (AmB) lipid complex (ABLC) in the treatment of AIDS-associated cryptococcal meningitis. Of 55 patients randomly assigned to 6 weeks of thera
Autor:
M S, Simberkoff, P M, Hartigan, J D, Hamilton, P L, Day, G R, Diamond, G M, Dickinson, G L, Drusano, M J, Egorin, W L, George, F M, Gordin, C A, Hawkes, P C, Jensen, N G, Kilmas, A M, Labriola, W A, O'Brien, C N, Oster, K J, Weinhold, N P, Wray, S B, Pazner
Publikováno v:
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association. 11(2)
Following a 4-year controlled trial comparing early and later zidovudine treatment, we conducted an additional 3-year follow-up. Of the original 338 patients, 275 participated. Clinical outcome measures were AIDS and death. In the early therapy group
Publikováno v:
The Journal of infectious diseases. 169(4)
Delayed-type hypersensitivity (DTH) testing was evaluated as a predictor of human immunodeficiency virus (HIV) disease progression in 336 symptomatic patients with baseline CD4 cell counts of 200-500/mm3 who were participating in a randomized trial o
Publikováno v:
Journal of acquired immune deficiency syndromes. 6(8)
A case-control study of patients with progressive (cases) or nonprogressive (controls) disease was designed to determine the association among disease progression, zidovudine sensitivity, and syncytium-inducing phenotype. Viral isolates were screened
Autor:
J D, Hamilton, P M, Hartigan, M S, Simberkoff, P L, Day, G R, Diamond, G M, Dickinson, G L, Drusano, M J, Egorin, W L, George, F M, Gordin
Publikováno v:
The New England journal of medicine. 326(7)
Zidovudine is recommended for asymptomatic and early symptomatic human immunodeficiency virus (HIV) infection. The best time to initiate zidovudine treatment remains uncertain, however, and whether early treatment improves survival has not been estab
Publikováno v:
Transactions of the Association of American Physicians. 104
Autor:
M. S. Simberkoff
Publikováno v:
JAMA: The Journal of the American Medical Association. 271:1875-1876